High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations. Existing strategies for reducing genome-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only partial or unproven efficacies and other limitations that constrain their use. Here we describe SpCas9-HF1, a high-fidelity variant harbouring alterations designed to reduce non-specific DNA contacts. SpCas9-HF1 retains on-target activities comparable to wild-type SpCas9 with >85% of single-guide RNAs (sgRNAs) tested in human cells. Notably, with sgRNAs targeted to standard non-repetitive sequences, SpCas9-HF1 rendered all or nearly all off-target events undetectable by genome-wide break capture and targeted sequencing methods. Even for atypical, repetitive target sites, the vast majority of off-target mutations induced by wild-type SpCas9 were not detected with SpCas9-HF1. With its exceptional precision, SpCas9-HF1 provides an alternative to wild-type SpCas9 for research and therapeutic applications. More broadly, our results suggest a general strategy for optimizing genome-wide specificities of other CRISPR-RNA-guided nucleases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Precision editing of alleles in a human cell has drastically improved the understanding of genotypic and phenotypic effects in gene therapy due to the lower off-target rates [119,120,121].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To address off-target issues, using the CRISPR system in the form of a rRNP and utilizing high-fidelity CRISPR variants can help minimize off-target effects (Kleinstiver et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Kleinstiver et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kleinstiver et al. developed the high-fidelity SpCas9-HF1, a variant that produced undetectable genome-wide off-target cleavage [134].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, a series of optimized mutations in SpCas9 have greatly improved the editing specificity of Cas9 variants without substantially attenuating the editing activity.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Some active gRNAs for SpCas9-WT showed very low editing ability in SpCas9 variants.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts199 · Cited by 20,027
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citation
Cited by
Items 301–400 of 1,016
CRISPR/Cas9-mediated noncoding RNA editing in human cancers
Yang, J., Meng, X., Pan, J., Jiang, N., Zhou, C., Wu, Z., & Gong, Z. (2017) · RNA Biology · doi:10.1080/15476286.2017.1391443 · Cited by 141
In vivo genome editing via the HITI method as a tool for gene therapy
Suzuki, K., & Belmonte, J. C. I. (2017) · Journal of Human Genetics · doi:10.1038/s10038-017-0352-4 · Cited by 131
Allosteric Motions of the CRISPR–Cas9 HNH Nuclease Probed by NMR and Molecular Dynamics
East, K. W., Newton, J. C., Morzan, U. N., Narkhede, Y. B., Acharya, A., Skeens, E., Jogl, G., Batista, V. S., Palermo, G., & Lisi, G. P. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10521 · Cited by 124
Engineering Delivery Vehicles for Genome Editing
Nelson, C. E., & Gersbach, C. A. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034711 · Cited by 118
Advanced CRISPR/Cas-based genome editing tools for microbial biofuels production: A review
Shanmugam, S., Ngo, H.-H., & Wu, Y.-R. (2020) · Renewable Energy · doi:10.1016/j.renene.2019.10.107 · Cited by 118
CRISPR Modeling and Correction of Cardiovascular Disease
Liu, N., & Olson, E. N. (2022) · Circulation Research · doi:10.1161/circresaha.122.320496 · Cited by 117
Huang, T. P., Heins, Z., Miller, S. M., Wong, B. G., Balivada, P. A., Wang, T., Khalil, A. S., & Liu, D. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01410-2 · Cited by 128
Precise and efficient scarless genome editing in stem cells using CORRECT
Kwart, D., Paquet, D., Teo, S., & Tessier‐Lavigne, M. (2017) · Nature Protocols · doi:10.1038/nprot.2016.171 · Cited by 128
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
Huang, C., Lee, K.-C., & Doudna, J. A. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.006 · Cited by 127
“Two variants, high-fidelity (SpCas9-HF1) [48] and enhanced specificity (eSpCas9(1.”
BackgroundGenome editing by natural and engineered CRISPR-associated nucleases
Wu, W. Y., Lebbink, J. H. G., Kanaar, R., Geijsen, N., & John van der, O. O. S. T. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0080-x · Cited by 124
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
Lonez, C., & Breman, E. (2024) · Cells · doi:10.3390/cells13020146 · Cited by 125
“In addition, a specific high-fidelity Cas9 mutant, called eSpCas9, did not cause any detectable off-target effect, making it an even safer technology [126,127].”
BackgroundBisht, D. S., Bhatia, V., & Bhattacharya, R. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.04.008 · Cited by 130
Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications
Li, Y., Glass, Z., Huang, M., Chen, Z., & Xu, Q. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119711 · Cited by 128
Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing
Waryah, C. B., Moses, C., Arooj, M., & Blancafort, P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7774-1_2 · Cited by 123
Gene therapy: a double-edged sword with great powers
Tang, R., & Xu, Z. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03834-3 · Cited by 134
CRISPR/Cas9: A Tool to Circumscribe Cotton Leaf Curl Disease
Iqbal, Z., Sattar, M. N., & Shafiq, M. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00475 · Cited by 126
“Importantly, Baltes et al. (2015) showed that designed sgRNA coupled with catalytically inactive Cas9 (dCas9) could control the BeYDV genome without cleaving the genome, hence, Cas9-HF (Kleinstiver et al., 2016; Slaymaker et al., 2016) or dCas9 (Baltes et al., 2015) could be used to eliminate the off-targets effects.”
BackgroundMethodInfluentialXie, Y., Wang, D., Lan, F., Wei, G., Ni, T., Chai, R., Liu, D., Hu, S., Li, M., Li, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02456-y · Cited by 122
Li, P., Kleinstiver, B. P., Leon, M. Y., Prew, M. S., Navarro-Gomez, D., Greenwald, S. H., Pierce, E. A., Joung, J. K., & Liu, Q. (2018) · The CRISPR Journal · doi:10.1089/crispr.2017.0009 · Cited by 116
Self-citationSchenke, D., & Cai, D. (2020) · iScience · doi:10.1016/j.isci.2020.101478 · Cited by 118
Wake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies
Wienert, B., Martyn, G. E., Funnell, A. P. W., Quinlan, K. G. R., & Crossley, M. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.09.004 · Cited by 115
Howden, S. E., McColl, B., Glaser, A., Vadolas, J., Petrou, S., Little, M. H., Elefanty, A. G., & Stanley, E. G. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.07.001 · Cited by 110
“Nonetheless, the incorporation of the Geminin peptide into the recently described high-fidelity versions of SpCas9 (SpCas9-HF1 and eCas9) (Kleinstiver et al., 2016; Slaymaker et al., 2016) may reduce the likelihood of off-target NHEJ further.”
BackgroundLessard, S., Francioli, L., Alfoldi, J., Tardif, J.-C., Ellinor, P. T., MacArthur, D. G., Lettre, G., Orkin, S. H., & Canver, M. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714640114 · Cited by 112
Gene drives to fight malaria: current state and future directions
Hammond, A., & Galizi, R. (2017) · Pathogens and Global Health · doi:10.1080/20477724.2018.1438880 · Cited by 119
Sharpening the Molecular Scissors: Advances in Gene-Editing Technology
Broeders, M., Herrero-Hernandez, P., Ernst, M. P. T., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2019) · iScience · doi:10.1016/j.isci.2019.100789 · Cited by 127
Principles of Genetic Engineering
Lanigan, T. M., Kopera, H. C., & Saunders, T. L. (2020) · Genes · doi:10.3390/genes11030291 · Cited by 133
Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics
Bhat, A. A., Nisar, S., Mukherjee, S., Saha, N., Yarravarapu, N., Lone, S. N., Masoodi, T., Chauhan, R., Maacha, S., Bagga, P., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03765-1 · Cited by 127
dCas9: A Versatile Tool for Epigenome Editing
Brocken, D. J. W., Tark-Dame, M., & Dame, R. T. (2018) · Current Issues in Molecular Biology · doi:10.21775/cimb.026.015 · Cited by 105
Hybridization Kinetics Explains CRISPR-Cas Off-Targeting Rules
Klein, M., Eslami-Mossallam, B., Arroyo, D. G., & Depken, M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.045 · Cited by 115
Efficient CRISPR–Cas9 mediated multiplex genome editing in yeasts
Wang, L., Deng, A., Zhang, Y., Liu, S., Liang, Y., Bai, H., Cui, D., Qiu, Q., Shang, X., Yang, Z., et al. (2018) · Biotechnology for Biofuels · doi:10.1186/s13068-018-1271-0 · Cited by 118
Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research
You, L., Tong, R., Li, M., Liu, Y., Xue, J., & Lü, Y. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.02.008 · Cited by 127
CRISPR/Cas9 for Human Genome Engineering and Disease Research
Xiong, X., Chen, M., Lim, W. A., Zhao, D., & Qi, L. S. (2016) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083115-022258 · Cited by 103
Genome editing: the road of CRISPR/Cas9 from bench to clinic
Eid, A., & Mahfouz, M. M. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.111 · Cited by 108
Lonowski, L. A., Narimatsu, Y., Riaz, A., Delay, C. E., Yang, Z., Niola, F., Duda, K., Ober, E. A., Clausen, H., Wandall, H. H., et al. (2017) · Nature Protocols · doi:10.1038/nprot.2016.165 · Cited by 112
Dwivedi, S. L., Scheben, A., Edwards, D., Spillane, C., & Ortiz, R. O. (2017) · Frontiers in Plant Science · doi:10.3389/fpls.2017.01461 · Cited by 119
Decoding non-random mutational signatures at Cas9 targeted sites
Taheri-Ghahfarokhi, A., Taylor, B. J. M., Nitsch, R., Lundin, A., Cavallo, A.-L., Madeyski-Bengtson, K., Karlsson, F., Clausen, M., Hicks, R., Mayr, L. M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky653 · Cited by 103
Engineered prime editors with PAM flexibility
Kweon, J., Yoon, J.-K., Jang, A.-H., Shin, H. R., See, J.-E., Jang, G., Kim, J.-I., & Kim, Y. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.022 · Cited by 109
Vargas, A. M. M., Sinha, S., Osborn, R. M., Arantes, P. R., Patel, A. C., Dewhurst, S., Hardy, D. J., Cameron, A., Palermo, G., & O’Connell, M. R. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad1132 · Cited by 119
Transforming plant biology and breeding with CRISPR/Cas9, Cas12 and Cas13
Schindele, P., Wolter, F., & Puchta, H. (2018) · FEBS Letters · doi:10.1002/1873-3468.13073 · Cited by 101
Rationally engineered Staphylococcus aureus Cas9 nucleases with high genome-wide specificity
Tan, Y., Chu, A. H. Y., Bao, S., Hoang, D. A., Kebede, F. T., Xiong, W., Ji, M., Shi, J., & Zheng, Z. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906843116 · Cited by 119
Self-citationComparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies
Castro, N. G. G., Bjelic, J., Malhotra, G., Huang, C., & Alsaffar, S. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910355 · Cited by 125
“1) (enhanced Streptococcus pyrogenes Cas9): structure-guided design weakens the binding affinity to the nontarget DNA strand; this improves specificity by reducing binding stability at off-target sites whilst maintaining on-target activity [149] 2-SpCas-HF1 (high fidelity): reduced cleaving ability at off-target sites…”
BackgroundGene Drive for Mosquito Control: Where Did It Come from and Where Are We Headed?
Macias, V. M., Ohm, J. R., & Rasgon, J. L. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14091006 · Cited by 124
Genome Editing Tools in Plants
Mohanta, T., Bashir, T., Hashem, A., Abd_Allah, E., & Bae, H. (2017) · Genes · doi:10.3390/genes8120399 · Cited by 106
Precision genome engineering through adenine and cytosine base editing
Kim, J. (2018) · Nature Plants · doi:10.1038/s41477-018-0115-z · Cited by 116
Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein
Chen, R., Huang, H., Liu, H., Xi, J., Ning, J., Zeng, W., Shen, C., Zhang, T., Yu, G., Xu, Q., et al. (2019) · Small · doi:10.1002/smll.201902686 · Cited by 104
Young, J. K., Zastrow‐Hayes, G., Deschamps, S., Svitashev, S. K., Zaremba, M., Acharya, A., Paulraj, S., Peterson-Burch, B. D., Schwartz, C. S., Djukanovic, V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43141-6 · Cited by 123
Plug-and-Play Protein Modification Using Homology-Independent Universal Genome Engineering
Gao, Y., Hisey, E., Bradshaw, T. W. A., Erata, E., Brown, W. E., Courtland, J. L., Uezu, A., Xiang, Y., Diao, Y., & Soderling, S. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.047 · Cited by 100
“High-fidelity spCas9 variants, including eSpCas9, SpCas9HF1, and HypaCas9, are reported to have less off-target tolerance (Chen et al., 2017; Kleinstiver et al., 2016; Slaymaker et al., 2016) and can be incorporated with the HiUGE method to further improve specificity.”
MethodCorrection of muscular dystrophies by CRISPR gene editing
Chemello, F., Bassel-Duby, R., & Olson, E. N. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136873 · Cited by 99
Eckerstorfer, M. F., Dolezel, M., Heissenberger, A., Miklau, M., Reichenbecher, W., Steinbrecher, R. A., & Waßmann, F. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00031 · Cited by 120
A glance at genome editing with CRISPR–Cas9 technology
Barman, A., Deb, B., & Chakraborty, S. (2019) · Current Genetics · doi:10.1007/s00294-019-01040-3 · Cited by 122
Targeted DNA insertion in plants
Dong, O. X., & Ronald, P. C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004834117 · Cited by 119
Advanced genetic tools enable synthetic biology in the oleaginous microalgae Nannochloropsis sp.
Poliner, E., Farré, E. M., & Benning, C. (2018) · Plant Cell Reports · doi:10.1007/s00299-018-2270-0 · Cited by 110
Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting
Charlesworth, C. T., Camarena, J., Cromer, M. K., Vaidyanathan, S., Bak, R. O., Carte, J. M., Potter, J., Dever, D. P., & Porteus, M. H. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.04.017 · Cited by 109
Engineering Epigenetic Regulation Using Synthetic Read-Write Modules
Park, M., Patel, N., Keung, A. J., & Khalil, A. S. (2019) · Cell · doi:10.1016/j.cell.2018.11.002 · Cited by 103
“VP12 humanSpCas9-Hf1 plasmid (Kleinstiver et al., 2016) Addgene: #72247”
Improving CRISPR Genome Editing by Engineering Guide RNAs
Moon, S. B., Kim, D. Y., Ko, J., Kim, J., & Kim, Y.-S. (2019) · Trends in biotechnology · doi:10.1016/j.tibtech.2019.01.009 · Cited by 111
Liao, C., Ttofali, F., Slotkowski, R., Denny, S. R., Cecil, T. D., Leenay, R. T., Keung, A. J., & Beisel, C. L. (2019) · Nature Communications · doi:10.1038/s41467-019-10747-3 · Cited by 118
CRISPR technologies for stem cell engineering and regenerative medicine
Hsu, M.-N., Chang, Y.-H., Truong, V. A., Lai, P.-L., Nguyen, T. K. N., & Hu, Y.-C. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107447 · Cited by 104
An overview and metanalysis of machine and deep learning-based CRISPR gRNA design tools
Wang, J., Zhang, X., Cheng, L., & Luo, Y. (2020) · RNA Biology · doi:10.1080/15476286.2019.1669406 · Cited by 102
“…of the available gRNA off-target data are measured based on high-throughput sequencing, like Guide_seq by Tsai et al. [48] and Kleinstiver et al. [76], Listgarten et al. [86], HTGTS [49], Digenome_seq [90], CIRCLE_Seq [91], and low-throughput techniques like target PCR and flanking PCR…”
BackgroundMethodCRISPR/Cas System and Factors Affecting Its Precision and Efficiency
Javaid, N., & Choi, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.761709 · Cited by 120
“A similar strategy was followed by another research group to design “high-fidelity SpCas9” (SpCas9-HF1) in which residues interacting with phosphate backbone of target DNA strand have been substituted with four alanine residues, unlike eSpCas9 (Kleinstiver et al., 2016).”
BackgroundMethodThe Conformational Dynamics of Cas9 Governing DNA Cleavage Are Revealed by Single-Molecule FRET
Yang, M., Peng, S., Sun, R., Lin, J., Wang, N., & Chen, C. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.048 · Cited by 111
Dastidar, S., Ardui, S., Singh, K., Majumdar, D., Nair, N., Fu, Y., Reyon, D., Samara-Kuko, E., Gerli, M., Klein, A. F., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky548 · Cited by 107
“Additionally, we note that it may be possible to further enhance on-target editing and minimize the risk of putative off-target effects by implementing our strategy using the latest generation of higher-fidelity CRISPR/Cas9 systems (90,91), which were developed and described as we were carrying out the current study.”
BackgroundSelf-citationLiu, M.-S., Gong, S., Yu, H.-H., Jung, K., Johnson, K. A., & Taylor, D. W. (2020) · Nature Communications · doi:10.1038/s41467-020-17411-1 · Cited by 95
Cas9 exo-endonuclease eliminates chromosomal translocations during genome editing
Yin, J., Lu, R., Xin, C., Wang, Y., Ling, X., Li, D., Zhang, W., Liu, M., Xie, W., Kong, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28900-w · Cited by 98
CRISPR/Cas9 gRNA activity depends on free energy changes and on the target PAM context
Corsi, G. I., Qu, K., Alkan, F., Pan, X., Luo, Y., & Gorodkin, J. (2022) · Nature Communications · doi:10.1038/s41467-022-30515-0 · Cited by 99
CRISPR engineering in organoids for gene repair and disease modelling
Geurts, M. H., & Clevers, H. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00013-5 · Cited by 103
Basics of genome editing technology and its application in livestock species
Petersen, B. (2017) · Reproduction in Domestic Animals · doi:10.1111/rda.13012 · Cited by 111
Functional Genomics via CRISPR–Cas
Ford, K. M., McDonald, D., & Mali, P. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.034 · Cited by 106
Highly efficient and precise base editing by engineered dCas9-guide tRNA adenosine deaminase in rats
Ma, Y., Yu, L., Zhang, X., Xin, C., Huang, S., Bai, L., Chen, W., Gao, R., Li, J., Pan, S., et al. (2018) · Cell Discovery · doi:10.1038/s41421-018-0047-9 · Cited by 99
Gene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G.-S. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 100
Genome Editing of Pigs for Agriculture and Biomedicine
Yang, H., & Wu, Z. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00360 · Cited by 111
Wang, Q., & Coleman, J. J. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.06.007 · Cited by 108
Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease
Ernst, M. P. T., Broeders, M., Herrero-Hernandez, P., Oussoren, E., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.022 · Cited by 107
Zhu, Y. (2022) · BioMed Research International · doi:10.1155/2022/9978571 · Cited by 117
“A mutant of Cas9, xCas9, is more precise than Cas9, can effectively reduce the off-target rate, and has been successfully used in gene therapy [153].”
Engineered CRISPR prime editors with compact, untethered reverse transcriptases
Grünewald, J., Miller, B. R., Szalay, R. N., Cabeceiras, P. K., Woodilla, C. J., Holtz, E. J. B., Petri, K., & Joung, J. K. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01473-1 · Cited by 100
Self-citationDong, P., Xiong, Y., Yue, J., Hanley, S. J. B., Kobayashi, N., Todo, Y., & Watari, H. (2019) · Cancers · doi:10.3390/cancers11020234 · Cited by 104
“Several techniques, such as SpCas9-HF1, a high-fidelity variant of SpCas9 that contains alterations in the amino acid sequence, have been utilized to reduce the off-target effects due to CRISPR/Cas9 [96,97].”
MethodHeat‐shock‐inducible CRISPR/Cas9 system generates heritable mutations in rice
Nandy, S., Pathak, B. P., Zhao, S., & Srivastava, V. (2019) · Plant Direct · doi:10.1002/pld3.145 · Cited by 105
“, high fidelity Cas9, split-Cas9, and ribonucleoprotein (RNP) Cas9 (Liang et al., 2017; Kleinstiver et al., 2016; Senturk et al., 2017; Svitashev et al., 2016; Wright et al., 2015).”
BackgroundGene Therapy for Cystic Fibrosis: Progress and Challenges of Genome Editing
Maule, G., Arosio, D., & Cereseto, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113903 · Cited by 110
Suzuki, Y., Onuma, H., Sato, R., Sato, Y., Hashiba, A., Maeki, M., Tokeshi, M., Kayesh, M. E. H., Kohara, M., Tsukiyama-Kohara, K., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.013 · Cited by 100
Ultrasound-Controlled CRISPR/Cas9 System Augments Sonodynamic Therapy of Hepatocellular Carcinoma
Yin, H., Sun, L., Pu, Y., Yu, J., Feng, W., Dong, C., Zhou, B., Du, D., Zhang, Y., Chen, Y., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c01143 · Cited by 108
Kato-Inui, T., Takahashi, G., Hsu, S., & Miyaoka, Y. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky264 · Cited by 108
Mollanoori, H., Shahraki, H., Rahmati, Y., & Teimourian, S. (2018) · Human Immunology · doi:10.1016/j.humimm.2018.09.007 · Cited by 109
Cx43 and Associated Cell Signaling Pathways Regulate Tunneling Nanotubes in Breast Cancer Cells
Tishchenko, A., Azorín, D. D., Vidal-Brime, L., Muñoz, M. J., Arenas, P. J., Pearce, C., Girao, H., Ramón y Cajal, S., & Aasen, T. (2020) · Cancers · doi:10.3390/cancers12102798 · Cited by 95
“To minimize putative off-target cleavage effects, we replaced the standard Cas9 with the VP12 high-fidelity Cas9 version [67].”
MethodDNA interference states of the hypercompact CRISPR–CasΦ effector
Pausch, P., Soczek, K. M., Herbst, D. A., Tsuchida, C. A., Al-Shayeb, B., Banfield, J. F., Nogales, E., & Doudna, J. A. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00632-3 · Cited by 107
Achieving Plant CRISPR Targeting that Limits Off‐Target Effects
Wolt, J. D., Wang, K., Sashital, D., & Lawrence‐Dill, C. J. (2016) · The Plant Genome · doi:10.3835/plantgenome2016.05.0047 · Cited by 93
Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics
Rose, J. C., Stephany, J. J., Valente, W. J., Trevillian, B. M., Dang, H. V., Bielas, J. H., Maly, D. J., & Fowler, D. M. (2017) · Nature Methods · doi:10.1038/nmeth.4368 · Cited by 101
Oggu, G. S., Sasikumar, S., Reddy, N., Ealla, K. K. R., Rao, C. M., & Bokara, K. K. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9760-2 · Cited by 105
Optimizing CRISPR/Cas9 for the Diatom Phaeodactylum tricornutum
Stukenberg, D., Zauner, S., Dell’Aquila, G., & Maier, U. G. (2018) · Frontiers in Plant Science · doi:10.3389/fpls.2018.00740 · Cited by 96
Kimberland, M. L., Hou, W., Alfonso-Pecchio, A. R., Wilson, S., Rao, Y., Zhang, S., & Lu, Q. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.08.007 · Cited by 109
Tadić, V., Josipović, G., Zoldoš, V., & Vojta, A. (2019) · Methods · doi:10.1016/j.ymeth.2019.05.003 · Cited by 107
Chen, Q., Zhang, Y., & Yin, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.014 · Cited by 103
Newsom, S. N., Parameshwaran, H. P., Martin, L., & Rajan, R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.619763 · Cited by 109
Hit and go CAS9 delivered through a lentiviral based self-limiting circuit
Petris, G., Casini, A., Montagna, C., Lorenzin, F., Prandi, D., Romanel, A., Zasso, J., Conti, L., Demichelis, F., & Cereseto, A. (2017) · Nature Communications · doi:10.1038/ncomms15334 · Cited by 98
CRISPR off-target detection with DISCOVER-seq
Wienert, B., Wyman, S. K., Yeh, C. D., Conklin, B. R., & Corn, J. E. (2020) · Nature Protocols · doi:10.1038/s41596-020-0309-5 · Cited by 100
CRISPR/Cas genome editing improves abiotic and biotic stress tolerance of crops
Li, Y., Wu, X., Zhang, Y., & Zhang, Q. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.987817 · Cited by 113
“Although much work has been done to optimize CRISPR/Cas system and improve its specificity, there is still no way to completely avoid editing individuals off-target (Pattanayak et al., 2013; Fu et al., 2014; Kleinstiver et al., 2016; Tang et al., 2019).”
BackgroundDesign of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy
Yu, J., Zhou, B., Zhang, S., Yin, H., Sun, L., Pu, Y., Zhou, B., Sun, Y., Li, X., Fang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35580-z · Cited by 104
CRISPR/Cas9 Landscape: Current State and Future Perspectives
Tyumentsev, A. I., Tyumentsev, A. I., & Акимкин, В. Г. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216077 · Cited by 112
“The problem of nonspecific editing is being solved by constructing (engineering) new variants of S. pyogenes Cas9 [15,24–41].”
BackgroundMethodInfluentialCRISPR-enhanced human adipocyte browning as cell therapy for metabolic disease
Tsagkaraki, E., Nicoloro, S. M. C., DeSouza, T., Solivan-Rivera, J., Desai, A., Lifshitz, L. M., Shen, Y., Kelly, M., Guilherme, A., Henriques, F. D. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27190-y · Cited by 99
Epigenome engineering: new technologies for precision medicine
Sgro, A., & Blancafort, P. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1000 · Cited by 99
“Examples of both are the enhanced eSpCas9 (K810A, K1003A, R1060A) (219), the high-fidelity SpCas9-HF1 (N497A, R661A, Q695A, Q926A) (220), followed by the hyper-accurate variant Hypa-SpCas9 (N692A, M694A, Q695A, H698A) (221), and the evolved evoSpCas9 (M495V, Y515N, K526E, R661Q) (223), all delivered in cells as plasmi…”
BackgroundA Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management
Ghosh, S., Sinha, J. K., Ghosh, S. K., Sharma, H., Bhaskar, R., & Narayanan, K. B. (2023) · Brain Sciences · doi:10.3390/brainsci13091305 · Cited by 111
“With CRISPR-Cas9, researchers can modify or delete epilepsy-related genes and investigate their impact on seizure susceptibility [194].”
BackgroundCRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges
Yi, L., & Li, J. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.002 · Cited by 112
Off‐target effects of engineered nucleases
Yee, J. (2016) · The FEBS Journal · doi:10.1111/febs.13760 · Cited by 93
Metadata
- Authors
- Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- City University of Hong Kong (HK)
- Corresponding author
- Joung, J. Keith
- ORCID
- Venue
- Nature
- Published
- 2016-01-06
- Volume
- 529
- Issue
- 7587
- Pages
- 490-495
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4851738
- OpenAlex
- W2224398381
- Cited by
- 2,673
- References
- 47
- Citations by year
- 2026: 189 · 2025: 221 · 2024: 200 · 2023: 181 · 2022: 267 · 2021: 273 · 2020: 287 · 2019: 284 · 2018: 284 · 2017: 267 · 2016: 215
- FWCI
- 181.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM107427, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, off-target mutations, Streptococcus pyogenes, single guide RNA, targeted sequencing, genome editing
- MeSH terms
- Base Sequence, DNA, DNA-Binding Proteins, Endonucleases, Genetic Engineering, Humans, Mutation, Protein Binding, RNA, Streptococcus pyogenes, Substrate Specificity, Reproducibility of Results, Genome, Human, Sequence Analysis, DNA, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.